Marianna Sansone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marianna Sansone has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bin Fang
Moffitt Cancer Center
11 shared publications - Ernst Schönbrunn
H. Lee Moffitt Cancer Center and Research Institute
11 shared publications - Jiandong Chen
Moffitt Cancer Center 1 Department of Molecular Oncology Tampa, Florida
11 shared publications - Justin M. Lopchuk
Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, United States
11 shared publications - Lihong Chen
Moffitt Cancer Center 1 Department of Molecular Oncology Tampa, Florida
11 shared publications - Mingxiang Teng
H. Lee Moffitt Cancer Center & Research Institute
11 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
The bromodomain-containing protein, transcription factor IID subunit 1 (TAF1; transcription factor II-250), is the largest component of the multiprotein assembly transcription factor IID, a dynamic complex that serves as a general factor for transcription initiation. CRISPR and RNAi screens of pan-cancer cell lines revealed that TAF1 is broadly required for optimal cell growth and survival, but a subset of cell lines showed enhanced TAF1 dependence. These observations suggest that TAF1 has the potential to serve as a therapeutic target in sensitive tumors. Current approaches employed to target TAF1 are limited to monovalent small-molecule inhibitors of the bromodomain. However, recent studies showed that such inhibitors lack cancer cell kill potential. We applied a structure-guided approach to generate cereblon recruiting Proteolysis Targeting Chimera (PROTAC) degraders of TAF1 using the chemical scaffolds of ceralasertib and GNE371. We present evidence that GNE371-based PROTACs are effective in degradation of TAF1 at concentrations as low as 1 nmol/L. TAF1 depletion activated p53 and induced apoptosis in acute myeloid leukemia (AML) cell lines and certain solid tumor cells. An in vivo active TAF1 PROTAC inhibited the growth of AML tumor xenografts. The results showed that inhibition of the bromodomain is not sufficient to inactivate TAF1 functions, whereas a PROTAC approach induces strong biological effects. Furthermore, TAF1 PROTACs have therapeutic potential against AML and other sensitive tumors.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
The bromodomain-containing protein, transcription factor IID subunit 1 (TAF1; transcription factor II-250), is the largest component of the multiprotein assembly transcription factor IID, a dynamic complex that serves as a general factor for transcription initiation. CRISPR and RNAi screens of pan-cancer cell lines revealed that TAF1 is broadly required for optimal cell growth and survival, but a subset of cell lines showed enhanced TAF1 dependence. These observations suggest that TAF1 has the potential to serve as a therapeutic target in sensitive tumors. Current approaches employed to target TAF1 are limited to monovalent small-molecule inhibitors of the bromodomain. However, recent studies showed that such inhibitors lack cancer cell kill potential. We applied a structure-guided approach to generate cereblon recruiting Proteolysis Targeting Chimera (PROTAC) degraders of TAF1 using the chemical scaffolds of ceralasertib and GNE371. We present evidence that GNE371-based PROTACs are effective in degradation of TAF1 at concentrations as low as 1 nmol/L. TAF1 depletion activated p53 and induced apoptosis in acute myeloid leukemia (AML) cell lines and certain solid tumor cells. An in vivo active TAF1 PROTAC inhibited the growth of AML tumor xenografts. The results showed that inhibition of the bromodomain is not sufficient to inactivate TAF1 functions, whereas a PROTAC approach induces strong biological effects. Furthermore, TAF1 PROTACs have therapeutic potential against AML and other sensitive tumors.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Synthetic chemistry procedures
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Synthetic chemistry procedures
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Table 2. RNA-seq analysis of differentially regulated genes after ZS3-046 treatment.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Table 2. RNA-seq analysis of differentially regulated genes after ZS3-046 treatment.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 5. TAF1 depletion by PROTAC activates p53.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 5. TAF1 depletion by PROTAC activates p53.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 3. Effects of TAF1 PROTAC on cell cycle profile.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 3. Effects of TAF1 PROTAC on cell cycle profile.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Table 3. Proteomics analysis of proteins affected by ZS3-046 treatment.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Table 3. Proteomics analysis of proteins affected by ZS3-046 treatment.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 1. TAF1 ligands used for PROTAC development.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 1. TAF1 ligands used for PROTAC development.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 4. AZD6738 PROTAC induces apoptosis independent of TAF1 degradation.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 4. AZD6738 PROTAC induces apoptosis independent of TAF1 degradation.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Table 1. Cell line sensitivity to TAF1 PROTAC induced cell death. Cells were treated with 200 nM ZS1-958 or 50 nM ZS3-025 for 48 to 96 hr. Apoptosis was determined by morphology and PARP cleavage.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Table 1. Cell line sensitivity to TAF1 PROTAC induced cell death. Cells were treated with 200 nM ZS1-958 or 50 nM ZS3-025 for 48 to 96 hr. Apoptosis was determined by morphology and PARP cleavage.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 2. TAF1 PROTAC has potent growth inhibition activity against AML cells.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
Supplemental Figure 2. TAF1 PROTAC has potent growth inhibition activity against AML cells.